HK inno.N tops 1 trillion won as profit jumps on K-CAB and vaccines

HK inno.N said on the 10th that its operating profit last year was 110.9 billion won, up 25.7% from a year earlier, based on preliminary figures.

Revenue for the same period rose 18.5% to 1.0631 trillion won, surpassing 1 trillion won in annual sales for the first time since the company's founding.

The growth appears to have been driven by solid sales of K-CAB, the country's 30th domestically developed new drug and a treatment for gastroesophageal reflux disease, along with infusion solutions and distribution of COVID-19 vaccines.

In the fourth quarter last year, revenue was 291.9 billion won, up 23.8% from a year earlier. Operating profit was 40.1 billion won, up 64.5% from a year earlier. Net profit came to 27.7 billion won.